A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Anlotinib Capsules for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)/Progressive Fibrosis-interstitial Lung Disease (PF-ILDs)
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Catequentinib (Primary)
- Indications Interstitial lung diseases; Pulmonary fibrosis
- Focus Therapeutic Use
- 13 Mar 2025 Planned End Date changed from 1 Jul 2025 to 31 Dec 2026.
- 13 Mar 2025 Planned primary completion date changed from 1 Aug 2024 to 31 Dec 2026.
- 17 Jul 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.